Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. is experiencing positive momentum in its growth, with EsoGuard test volumes increasing by 2% year-over-year to 2,841 tests in 3Q25, surpassing initial estimates. The company is expected to achieve rapid revenue growth as it expands coverage through Medicare and various insurance plans, enhancing accessibility to its critically important diagnostic tools. Additionally, a favorable MolDX CAC meeting indicates potential for positive Medicare coverage decisions, which could significantly enhance the company's market reach and financial performance, presenting considerable upside potential.

Bears say

Lucid Diagnostics reported a pro forma net loss of $9.9 million for Q3 2025, slightly exceeding both internal estimates and consensus projections, which highlights ongoing financial challenges. Additionally, the decline in EsoGuard test processing, down to 2,756 tests in Q2 from previous quarters, raises concerns over the slowing adoption of their flagship product amidst competitive pressures and potential reimbursement issues. Coupled with significant risks related to product efficacy, regulatory approvals, and broader liquidity concerns, the company faces a precarious outlook that may hinder future growth and profitability.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.